Summit Therapeutics (SMMT) Reveals Phase II AK112-206 Trial Data
Key takeaways
- Summit Therapeutics (SMMT) Reveals Phase II AK112-206 Trial Data Muhammad Ali Khalid Fri, June 5, 2026 at 11:36 PM GMT+7 2 min read SMMT 9926.HK Summit Therapeutics Inc.
- (NASDAQ:SMMT) presented new clinical data from the international Phase II AK112-206 trial during the American Society of Clinical Oncology.
- According to the study, treatment-naive patients in the U.S. and China receiving this novel therapeutic in combination with standard mFOLFOX6 chemotherapy showed a strong objective response rate of 70.8%.
Summit Therapeutics (SMMT) Reveals Phase II AK112-206 Trial Data Muhammad Ali Khalid Fri, June 5, 2026 at 11:36 PM GMT+7 2 min read SMMT 9926.HK Summit Therapeutics Inc. (NASDAQ:SMMT) is one of the 10 best large cap stocks under $30 with highest upside potential.
On May 31, Summit Therapeutics Inc. (NASDAQ:SMMT) presented new clinical data from the international Phase II AK112-206 trial during the American Society of Clinical Oncology. Co-sponsored alongside Akeso, this multisite study evaluates the potential first-in-class bispecific antibody named ivonescimab, for patients battling first-line metastatic colorectal cancer.
According to the study, treatment-naive patients in the U.S. and China receiving this novel therapeutic in combination with standard mFOLFOX6 chemotherapy showed a strong objective response rate of 70.8%. When compared to the previous performance of standard-of-care regimens that mix bevacizumab with traditional FOLFOX chemotherapy, it is seen that these clinical outcomes are quite promising.